Search results
Results from the WOW.Com Content Network
Rifaximin, sold under the brand name Xifaxan among others, is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of gastrointestinal diseases like ...
When rifaximin is added to lactulose, the combination of the two may be more effective than each component separately. [4] Rifaximin is more expensive than lactulose, but the cost may be offset by fewer hospital admissions for encephalopathy. [19] The antibiotics neomycin and metronidazole are other antibiotics used to treat hepatic ...
The hallmark symptom of LATE is a progressive memory loss that predominantly affects short-term and episodic memory. [1] This impairment is often severe enough to interfere with daily functioning and usually remains the chief neurologic deficit, unlike other types of dementia in which non-memory cognitive domains and behavioral changes might be noted earlier or more prominently. [1]
Rifaximin is an oral rifamycin marketed in the US by Salix Pharmaceuticals that is poorly absorbed from the intestine. It has been used to treat hepatic encephalopathy and traveler's diarrhea . [ 19 ]
The Mayo Clinic Cancer Center is one of the oldest NCI-designated cancer centers in the United States, having first been designated in 1973. [3] The main location of the Mayo Clinic is in Rochester, MN. Campuses in Arizona and Florida opened later and became part of the Mayo Clinic Cancer Center in 2003. [4] [5]
Mayo Clinic Health System is a system of community-based medical facilities. It is owned by Mayo Clinic and was founded in 1992. The organization focuses on providing medical care in rural communities in Minnesota , Iowa , and Wisconsin .
Center for Stem Cell and Regenerative Medicine: developing basic and clinical research programs, biomedical and tissue engineering programs, and the development and administration of new therapies to patients; Armed Forces Institute of Regenerative Medicine: developing clinical therapies for military-related injuries
A regenerative medicine therapy is defined in section 506(g)(8) of the FD&C Act to include cell therapies, therapeutic tissue engineering, human cell and tissue products. Under the FDA's interpretation, gene therapies and genetically modified cells that have a lasting effect, such as CAR-T antitumor therapies, may also qualify as regenerative ...